Wang L.,Shanghai JiaoTong University |
Hu J.,Shanghai JiaoTong University |
Sun Y.,Peking University |
Huang H.,Zhejiang University |
And 14 more authors.
Medicine (United States) | Year: 2016
Invasive fungal infection (IFI) remains as a significant cause of morbidity and mortality in patients with acute myelogenous leukemia (AML). Here, we report the subgroup analysis of China Assessment of Antifungal Therapy in Haematological Disease (CAESAR) study to evaluate the risk of IFI in patients with AML in 1st remission receiving high-dose cytarabine (HiDAC) as consolidation. A total of 638 patients with AML in 1st complete remission were selected from the database. Among them, 130 patients received HiDAC alone with total dose of 2- 3 g/m2×6 while 508 patients received multiple-Agent combination chemotherapy (multiagent chemo group). The patients' characteristics were generally not different but more patients in HiDAC group had peripherally inserted central catheter (61.5% vs 44.5%, P=0.002). The median duration of neutropenia was 8.0 days in both HiDAC (2-20) and multiagent chemo group (2-28). Number of patients with prolonged neutropenia (>14 days) tended to be more in multiagent chemo group but not significant different (16.3% vs 8.8%, respectively). There was no significant difference between 2 groups in persistent neutropenic fever (40.8% vs 33.1%), antifungal treatment (11.5% vs 11.4%), and incidence of proven/probable IFI (4 probable in HiDAC vs 1 proven/4 probable in multiagent chemo, P=0.35) or possible IFI. As to the clinical outcome in terms of duration of hospitalization and death in remission, there was a trend of shorter duration of hospitalization in HiDAC (19 days, 3-70) compare to multiagent chemo group (21 days, 1-367, P=0.057) while no death documented in HiDAC group and only 2 patients died in the multiagent chemo group (0.4%). As to risk factors associated with IFI in all 638 patients, there was a trend of more IFI in patients with severe neutropenia (3.0%, P=0.089) and previous history of IFI (3.85%, P=0.086) while the antifungal prophylaxis was not associated significantly reduced IFI. Overall, our data support the perception that HiDAC alone as consolidation in first remission AML patients was well tolerated and not associated with increased hematological toxicity and IFI than conventional combination chemotherapy. Antifungal prophylaxis may not necessary except for patients with previous history of IFI. Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.
Xie M.,Southern Medical University |
Huang H.,Southern Medical University |
Hang J.,Southern Medical University |
Dong Z.,Guangzhou Dari Antibody Engineering and Technology Co. |
And 4 more authors.
Journal of Immunoassay and Immunochemistry | Year: 2015
We developed a TR-FIA kit for quantitative detection of CA50. This study aims to evaluate the analytical and clinical performances of this kit. Precision, accuracy, specificity, sensitivity, stability, and endogenous interference of this kit are evaluated. Reference range is established. Coincidence rate and correlation between TR-FIA and RIA are evaluated. ROC is adopted to evaluate the diagnostic performance. This kit shows excellent precision with a coefficients of variation (CVs) ranged from 2.2-9.3%, accuracy (average recovery, 98.5%), sensitivity (minimum detectable concentration is 0.2 U/mL), specificity (all cross-reactivity is less than 0.1% except CA199, which is 0.175%), and storage stability (recoveries, 90.8-100.4%). Bilirubin, hemoglobin, and triglyceride dose not interfere with CA50 detection (recovery, 97.13-109.1%). The range from 0-25 U/mL is chosen as the reference range. There are good correlation (r = 0.804) and coincidence (p = 0.608, kappa = 0.924) between TR-FIA and RIA. Diagnostic performance of this kits, which based on RIA results, is perfect (AUC = 0.996), and the diagnostic accuracy for malignancy diagnosis is in moderate degree (AUC, 0.802-0.861). The TR-FIA (CA50) kit performs well in analytical and clinical performances, and can be employed in the clinical diagnosis of malignancy. © Copyright © Taylor & Francis Group, LLC.
Li C.-G.,Dalian Medical University |
Li M.-L.,Dalian Medical University |
Shu X.-H.,Dalian Medical University |
Liu Y.-J.,Dalian Medical University |
Wu W.-S.,First Peoples Hospital of Shanghai
Cancer Chemotherapy and Pharmacology | Year: 2010
Purpose: An apoptosis-inducing therapy is gradually becoming a new strategy for cancer treatment. The aim of this study was to investigate the mechanism of growth-inhibitory effects of recombinant human interleukin-6 (rhIL-6) on bladder tumor-bearing T739 mice in vivo. Methods: Murine bladder transitional carcinoma cells (BTT739) were inoculated subcutaneously into T739 mice as a tumor model for evaluating the antitumor effects of rhIL-6. Then the mice were divided randomly into 5 groups: A, B, C, D and E. Different doses (0, 2, 4, 8 × 106 IU/kg body weight) of rhIL-6 were injected intraperitoneally twice per day and administered for 14 days, and 1 mg/kg/d mitomycin-C(MMC) was used as control. Tumor size was measured and determined as the mean of the largest diameter and the diameter at right angle. Animals were killed by CO2 inhalation on the 15th day after tumor cell inoculation. Then, tumors were removed, weighed and collected. The tumor growth inhibition rate of rhIL-6 was calculated. The morphological characteristic changes of tumor cells were observed under electron microscope, and cell cycle analysis was determined by flow cytometry. The expressions of Fas, FasL and Bcl-2 protein on tumor cells were qualitatively detected by immunofluorescence cell staining, and their relative contents (rate of positive cells, RPC) were quantitatively determined with flow cytometry. Results: rhIL-6 could inhibit bladder tumor growth in a dose-dependent manner in vivo. The tumor growth-inhibitory rates of 2, 4, 8 × 106 IU/kg rhIL-6 and 1 mg/kg MMC were 11.8, 39.5, 39.7 and 68.8%, respectively. Flow cytometry results showed that a hypodiploid peak before G1 phase could be found in tumor cells treated with rhIL-6. Moreover, the cells treated with rhIL-6 displayed disappearance of nucleoli, chromatin gathering under the nuclear membrane in mass or ring-shape under transmission electron microscopy. The rates of Fas, FasL protein-positive cells estimated by flow cytometry in rhIL-6-treated mice were (12.57 ± 0.83) and (20.1 ± 0.87) %, respectively, significantly higher than that (4.66 ± 0.17) and (14.1 ± 0.83) % in control mice (P < 0.01). There was no significant difference in the rate of Bcl-2 protein-positive cells between the mice in these two groups (P > 0.05). Conclusions: rhIL-6 had obvious antitumor effects on mouse bladder carcinoma in vivo, and the Fas signaling pathway might play an important role in rhIL-6-induced bladder carcinoma cell apoptosis. © 2010 Springer-Verlag.
Wang Y.-C.,Ninth Peoples Hospital Of Ningbo City |
Zhang Q.-F.,First Peoples Hospital Of Shanghai
Chinese Journal of Tissue Engineering Research | Year: 2014
BACKGROUND: Tendon cells are characterized by high differentiation potentials, slow proliferation rate, and even lost proliferation capacity after passage in vitro. Therefore it is necessary to establish the ideal isolation and culture patterns of tendon cells in vitro. OBJECTIVE: To investigate the isolation, culture and identification of tendon cells. METHODS: The flexor tendon of New Zealand fetal rabbits were cut under sterile conditions, the peritenon of flexor tendon was removed by microsurgical technique. Tendon cells were isolated with Henderson-step enzymatic digestion method and cultured in a complete medium consisting of DMEM/F12 and 20% fetal bovine serum for primary culture and passage. RESULTS AND CONCLUSION: The tendon cells with high purity can be successfully isolated by different enzymatic digestion methods, and the cultured cells well proliferated and passaged in vitro. The immunohistochemical staining showed that, passage 2 cells were positive for collagen type I antibody, but negative for collagen type III antibody. These evidences confirmed that the cultured cells are tendon cells. Tendon cells can be isolated, proliferated and passaged in vitro. © 2014, Journal of Clinical Rehabilitative Tissue Engineering Research. All right resurved.
Zhu Z.-H.,First Peoples Hospital of Shanghai |
Shen Q.,First Peoples Hospital of Shanghai
Chinese Journal of Tissue Engineering Research | Year: 2014
Background: Studies have shown that neural stem cells isolated from embryonic rat cerebral cortex can proliferate and differentiate into neurons, astrocytes and oligodendrocytes in collagen gels. Objective: To investigate the effect of neural stem cells combined with collagen gel on the apoptosis of nerve cells in the brain of rats after spinal cord injury. Methods: Forty-five spinal cord injury rat models were made through spinal cord hemisection and randomly divided into three groups. At 1 week after modeling, rats in the cell transplantation group were injected allogeneic neural stem cell suspension into the injured site, rats in the combination group were administered with allogeneic neural stem cells/collagen gel suspension into the injured site, and rats in the model group received no treatment. Results And Conclusion: From 1 to 8 weeks after injury, the Basso, Beattie and Bresnahan (BBB) locomotion scores in the combination group were significantly higher than those in the other two groups (P < 0.05). Hematoxylin-eosin staining showed that at 1 week after transplantation, there were a few necrotic cells and Bcl-2 positive cells, but a large amount of Bax positive cells in the three groups. Then, the number of Bax- and Bcl-2-positive cells was reduced graduallyin the three groups. At 8 weeks after transplantation, the number of Bax-positive cells was significantly higher in the model group than the other two group (P < 0.05), but the number of Bcl-2-positive cells were dramatically lower (P < 0.05). Meanwhile, there were no necrotic cells in the three groups. These findings indicate that neural stem cell transplantation combined with collagen gel scaffold can arrest apoptosis of nerve cells in the brain of rats after spinal cord injury, and promote functional recovery after spinal cord injury.
Qi X.,First Peoples Hospital of Shanghai |
Sun X.,First Peoples Hospital of Shanghai |
Xu J.,First Peoples Hospital of Shanghai |
Wang Z.,First Peoples Hospital of Shanghai |
And 2 more authors.
Tumor Biology | Year: 2014
Genetic polymorphisms of methylenetetrahydrofolate reductase (MTHFR) gene are considered to have some influence on both folate metabolism and cancer risk. Previous studies on the associations of MTHFR genetic polymorphisms with hepatocellular carcinoma (HCC) risk in Chinese population reported inconsistent results. We performed this meta-analysis to comprehensively assess the associations. Finally, 12 individual case-control studies were included into the meta-analysis. There were seven studies (6,384 subjects) on the MTHFR C677T polymorphism and five studies (4,502 subjects) on the MTHFR A1298C polymorphism. Overall, MTHFR C677T polymorphism was significantly associated with susceptibility to HCC in Chinese population (T versus C, odds ratio (OR) = 1.09, 95 % confidence interval (95 % CI) 1.01-1.17; TT versus CC, OR = 1.17, 95 % CI 1.00-1.38; TT/CT versus CC, OR = 1.12, 95 % CI 1.00-1.26). MTHFR A1298C polymorphism was conversely associated with HCC risk in Chinese population (CC versus AA, OR = 0.65, 95 % CI 0.46-0.91; CC versus AA/AC, OR = 0.64, 95 % CI 0.46-0.90). The sensitivity analysis confirmed the reliability and stability of the meta-analysis. Thus, the findings from our meta-analysis support the associations of MTHFR C677T and A1298C polymorphisms with HCC risk in Chinese population. © 2014 International Society of Oncology and BioMarkers (ISOBM).